UFP Technologies, Inc. Q4 FY2025 earnings call

Jeff mentioned 2025 sales growth, strategic initiatives progress including contract extensions, program launches, facility expansions, and HR talent. Ron discussed fourth quarter and year-end results, network security incident detection and response, operational sales growth drivers, gross margin impact from AJR labor inefficiencies, adjusted operating margin within target, cash generation, acquisition integrations progress, and CEO transition planning.

Full year sales grew 19.5% to $602.8 million. Operating income grew 435% and EPS grew 419% since 2021. Fourth quarter AJR E-Verify labor inefficiency was $1.2 million, less than Q3's $3.0 million. Dominican Republic expansions: Santiago launched second major program, La Romana launched three new programs, fifth building complete, sixth building to be taken in April. Contract extended with largest customer, infection prevention contract extended to 2030, orthopedic sterile packaging won new business.

Contract extension details not specific but material increase. AJR labor inefficiency impact expected to decrease in Q1 and beyond. 2026 medtech growth expected robust with patient services, new programs in infection prevention and robotic surgery. Sixth building to be taken in April with capacity expansion.

Cybersecurity breach detected on Feb 14, ransomware attack, data taken and destroyed, but backup systems allowed operation, minimal impact on operations expected, investigation ongoing.

Q: Good news around the contract extension. Could you provide any directional color on how we should think about volumes with your largest customer in 2026 and 2027?

A: The contract extension is great news but customers asked not to give specifics on volume increase.

Q: Regarding the headwind at AJR, how are you thinking about this impact in Q1?

A: Q1 will have some impact, less than Q4, and will diminish.

Q: Can you give more color on the puts and takes of the flat medtech growth?

A: Expect robust growth in patient services market, new programs in infection prevention and robotic surgery.

Q: On the cybersecurity incident, is there any disruption in business that will impact growth rates?

A: Delay in shipping but back online, minimal material impact on Q1.

Q: A few here around the contract extension, just around the facility. Are you on the hook for that entire investment?

A: With major contracts, there is co-investment, take possession of sixth building in April.

Q: You called out safe patient handling in the press release. Is there any way you can size that opportunity?

A: It's a large and growing market with double-digit growth.

Q: A few here around the contract extension, just around the facility. Timeline of completion of that facility?

A: Take possession in April, start setup.

Q: A few here around the contract extension, just around the new programs. Are those the three, or is there an additional program?

A: Three programs, two robotic surgery and one infection prevention.

Q: On the AJR business, how should we think about the pacing of backlog?

A: Backlog to be worked down gradually in 2026.